2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Cell Expansion, Clinical Procedures, Emerging Technologies, Treatment Considerations, Combination Therapy, Therapy Sequence, Biological Therapies, Transplantation, (CAR)-T Cell Therapies, Infusion, Adverse Events, Clinical Practice (Health Services and Quality), Quality Improvement, Value, Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, ALL, B Cell Lymphoma, Research, Translational Research, Clinical Research, Study Population, Human, Adult, Elderly
PAPER

2422 Iterative process development enables clinical translation of the logic-gated dCAR138-38 CAR T cell product

Orit Berhani Zipori, PhD, Shimrit Suliman, MS2, Shani Drucker, MS3, Ilana Kalnitsky, MS4, Anatoly Shneyer, MS5, Gilad Gross, MS6, Tamir Shragai, MD7, Yair Herishanu, Prof8, Irit Avivi Mazza, MD9, Anat Globerson Levin, PhD10, Yael C. Cohen, MD11
1 Institute for Advanced Cellular Therapies (I-ACT), Tel Aviv Sourasky University Medical Center (Ichilov), Tel Aviv, Israel
2 Institute for Advanced Cellular Therapies (I-ACT), Tel Aviv Sourasky University Medical Center (Ichilov), Tel Aviv, Israel
3 Institute for Advanced Cellular Therapies (I-ACT), Tel Aviv Sourasky University Medical Center (Ichilov), Tel Aviv, Israel
4 Institute for Advanced Cellular Therapies (I-ACT), Tel Aviv Sourasky University Medical Center (Ichilov), Tel Aviv, Israel
5 Institute for Advanced Cellular Therapies (I-ACT), Tel Aviv Sourasky University Medical Center (Ichilov), Tel Aviv, Israel
6 Institute for Advanced Cellular Therapies (I-ACT), Tel Aviv Sourasky University Medical Center (Ichilov), Tel Aviv, Israel
8 Gray Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv, Israel, Tel Aviv Sourasky University Medical Center (Ichilov), Tel Aviv, Israel
9 Gray Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv, Israel, Tel Aviv Sourasky University Medical Center (Ichilov), Tel Aviv, Israel
10 Dotan Center for Advanced Therapies, TASUMC and TAU, Tel Aviv, Israel, Gray Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv, Israel, Immunology and Advanced CAR T Therapy, Tel Aviv Sourasky University Medical Center (Ichilov), Tel Aviv, Israel
11 Gray Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv, Israel, Tel Aviv Sourasky University Medical Center (Ichilov), Tel Aviv, Israel

Background
Relapsed/refractory multiple myeloma (RRMM) remains incurable in some patients, despite major advances in immunotherapy, thus further therapies are needed. dCAR138-38 is a first-in-class autologous logic-gated CAR T-cell targeting CD138 and CD38 that employs split signaling, requiring simultaneous recognition of both antigens for full T-cell activation. This dual-target architecture improves discrimination between malignant and healthy cells while reducing on-target/off-tumor toxicity. However, the Fcγ receptor-derived CD38 recognition domain has been associated with low-level CAR-mediated fratricide, suggesting that conventional CAR T-cell manufacturing approaches may not be optimal for this construct. We therefore sought to develop a manufacturing process tailored to dCAR138-38 biology.

Methods
Manufacturing optimization was performed using T cells from 7 healthy donors (HD) and 5 heavily pre-treated RRMM patients, including two previously treated with BCMA-directed CAR T cells. Initial GMP manufacturing employed the automated closed-system manufacturing platform, followed by evaluation of gas-permeable culture vessels and CellStack process optimization. Seeding density, culture volume and expansion strategy were systematically optimized before translation to full-scale CellStack manufacturing. Cell expansion, viability, CAR transduction, T-cell phenotype, and functional activity were assessed throughout manufacturing.

Results
Analysis of 17 GMP manufacturing and process development runs using the automated closed-system manufacturing platform demonstrated persistently suboptimal harvest viability (77.3±5.5%) and CAR transduction (51.9±10.9%), frequently limiting production of the target high dose (10×106 CAR T cells/kg). Post-formulation stability testing demonstrated declining viability below release criteria by 10hrs, limiting product stability to 6 hours.
To improve manufacturing performance gas-permeable static culture vessels were evaluated. Although robust expansion was achieved, harvest viability (mean 83.2±13.7%) and CAR transduction rates (mean 49.2±8.64%) remained suboptimal. HD cultures demonstrated greater early expansion than patient samples (Day 3-6, fold expansion 8.9 vs. 4.5) but reduced late expansion (Day 6-10, fold expansion 6.7 vs. 14.3), coinciding with declining viability. Further analysis revealed a strong negative correlation between Day 6 culture density and Day 10 harvest viability (r=-0.82), suggesting that increased cell density, through excessive cell-cell interactions, may enhance the low-level CAR-mediated fratricide previously reported for dCAR138-38.
These findings prompted development of a CellStack-based process that increased culture surface area while maintaining controlled cell density. CellStack optimization defined an optimal seeding density, culture volume, and expansion strategy. The optimized process increased mean harvest viability to 90.0±5.3% and CAR transduction to 66.2±8.2%, representing an approximate 30% relative improvement over previous platforms.  Final T cell subset composition remained comparable across manufacturing platforms. dCAR138-38 CAR T cells consistently mediated antigen-specific cytotoxicity against CD38/CD138-positive target cells, with ≥70% specific killing observed at higher E:T ratios. The optimized process has since been successfully translated to full-scale CellStack manufacturing, with initial stability results of the product remaining steady for up to 24hrs (T=0 94.9%±0.82%, T=24 90.7%±3.03%) demonstrating improved cellular integrity following manufacture.

Conclusions
The biological characteristics of the logic-gated dCAR138-38 CAR impose manufacturing constraints not typically encountered with conventional CAR T-cell products. Iterative process development identified culture density as a critical manufacturing parameter leading to the development of an optimized CellStack-based strategy that substantially improved harvest viability and CAR transduction while providing a scalable, GMP-compatible process for clinical translation. These findings demonstrate that manufacturing strategies for next-generation logic-gated CAR T-cell products should be tailored to their unique biology rather than adapted from conventional CAR T-cell platforms, supporting progression to a Phase 1 clinical trial.

Yael C. Cohen, MD: BMS - Honoraria; NeoPharm - Honoraria; GSK - Honoraria; Janssen - Honoraria; Takeda - Honoraria; Amgen - Honoraria; Medison - Honoraria; Sanofi - Honoraria; Janssen - Research Funding; GSK - Research Funding; Takeda - Research Funding; Karyopharm Therapeutics - Research Funding; Sanofi - Research Funding; Amgen - Research Funding; BMS - Research Funding; Sanofi - Consultancy (Includes expert testimony); Janssen - Consultancy (Includes expert testimony); BMS - Consultancy (Includes expert testimony); Medison - Consultancy (Includes expert testimony); Amgen - Consultancy (Includes expert testimony); GSK - Consultancy (Includes expert testimony); Takeda - Consultancy (Includes expert testimony)